Literature DB >> 18976422

Intravitreal triamcinolone acetonide injection for acute non-arteritic anterior ischaemic optic neuropathy.

Aylin Yaman1, Ozlem Barut Selver, A Osman Saatci, Meltem F Soylev.   

Abstract

Non-arteritic anterior ischaemic optic neuropathy is the most common optic neuropathy of the elderly, characterised by unilateral, sudden, painless visual loss. No effective treatment has been proven to reverse or limit the course of this disease. We evaluated the role of intravitreal triamcinolone acetonide injection in eyes with non-arteritic anterior ischaemic optic neuropathy (NAION). Four eyes of four patients with acute NAION received a single intravitreal injection of triamcinolone acetonide (4 mg). The time between visual loss and intravitreal injection varied between four and 10 days. Mean age of patients was 57.25 years (range, 44 to 77 years). All patients experienced some visual gain. No complications related to the injection were observed during the following three months. Intravitreal triamcinolone injection may offer help in limiting the damage in this small group of patients with a relatively short history of visual loss due to NAION.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18976422     DOI: 10.1111/j.1444-0938.2008.00287.x

Source DB:  PubMed          Journal:  Clin Exp Optom        ISSN: 0816-4622            Impact factor:   2.742


  15 in total

1.  Intravitreal triamcinolone injections in non-arteritic anterior ischemic optic neuropathy.

Authors:  Corina Radoi; Tony Garcia; Catherine Brugniart; Alain Ducasse; Carl Arndt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-11-01       Impact factor: 3.117

2.  Should steroids be offered to patients with nonarteritic anterior ischemic optic neuropathy?

Authors:  Andrew G Lee; Valérie Biousse
Journal:  J Neuroophthalmol       Date:  2010-06       Impact factor: 3.042

3.  Urologic medications and ophthalmologic side effects: a review.

Authors:  Johan Gani; Nathan Perlis; Sidney B Radomski
Journal:  Can Urol Assoc J       Date:  2012-02       Impact factor: 1.862

4.  Nonarteritic anterior ischemic optic neuropathy.

Authors:  Edward J Atkins
Journal:  Curr Treat Options Neurol       Date:  2011-02       Impact factor: 3.598

Review 5.  Treatment of nonarteritic anterior ischemic optic neuropathy.

Authors:  Edward J Atkins; Beau B Bruce; Nancy J Newman; Valérie Biousse
Journal:  Surv Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 6.048

6.  Intravitreal bevacizumab for the treatment of nonarteritic anterior ischemic optic neuropathy: a prospective trial.

Authors:  D B Rootman; H S Gill; E A Margolin
Journal:  Eye (Lond)       Date:  2013-02-01       Impact factor: 3.775

7.  Can subtenon methylprednisolone acetate be a choice for the acute non-arteritic ischemic optic neuropathy treatment?

Authors:  Mahmut Oğuz Ulusoy; Sertaç Argun Kıvanç; Mehmet Atakan
Journal:  Rom J Ophthalmol       Date:  2016 Oct-Dec

8.  Single intravitreal aflibercept injection for unilateral acute nonarteritic ischemic optic neuropathy.

Authors:  Ziya Ayhan; Gamze Kocaoğlu; Aylin Yaman; Meltem Söylev Bajin; A Osman Saatci
Journal:  Case Rep Ophthalmol Med       Date:  2015-01-08

9.  Efficacy of intravitreal ranibizumab injection in acute nonarteritic ischemic optic neuropathy: a long-term follow up.

Authors:  Ali Osman Saatci; Okan Taskin; Ozlem Barut Selver; Aylin Yaman; Meltem Soylev Bajin
Journal:  Open Ophthalmol J       Date:  2013-09-30

Review 10.  Translational Preclinical Research may Lead to Improved Medical Management of Non-Arteritic Anterior Ischemic Optic Neuropathy.

Authors:  James D Nicholson; Hana Leiba; Nitza Goldenberg-Cohen
Journal:  Front Neurol       Date:  2014-07-11       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.